Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
:HALO
Total Valuation
Halozyme has a market cap or net worth of $8.12B. The enterprise value is ―.
Market Cap$8.12B
Enterprise Value―
Share Statistics
Halozyme has 123,221,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding123,221,000
Owned by Insiders1.09%
Owned by Institutions1.95%
Financial Efficiency
Halozyme’s return on equity (ROE) is 1.22 and return on invested capital (ROIC) is 22.84%.
Return on Equity (ROE)1.22
Return on Assets (ROA)0.22
Return on Invested Capital (ROIC)22.84%
Return on Capital Employed (ROCE)0.29
Revenue Per Employee2.90M
Profits Per Employee1.27M
Employee Count350
Asset Turnover0.49
Inventory Turnover1.12
Valuation Ratios
The current PE Ratio of Halozyme is 13.65. Halozyme’s PEG ratio is 1.33.
PE Ratio13.65
PS Ratio0.00
PB Ratio22.18
Price to Fair Value16.67
Price to FCF16.84
Price to Operating Cash Flow16.84
PEG Ratio1.33
Income Statement
In the last 12 months, Halozyme had revenue of 1.02B and earned 444.09M in profits. Earnings per share was 3.50.
Revenue1.02B
Gross Profit855.91M
Operating Income551.48M
Pretax Income557.13M
Net Income444.09M
EBITDA656.54M
Earnings Per Share (EPS)3.50
Cash Flow
In the last 12 months, operating cash flow was 479.06M and capital expenditures -10.70M, giving a free cash flow of 468.37M billion.
Operating Cash Flow479.06M
Free Cash Flow468.37M
Free Cash Flow per Share3.80
Dividends & Yields
Halozyme pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.89
52-Week Price Change52.67%
50-Day Moving Average61.57
200-Day Moving Average56.50
Relative Strength Index (RSI)60.23
Average Volume (3m)1.96M
Important Dates
Halozyme upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Halozyme as a current ratio of 7.80, with Debt / Equity ratio of 413.88%
Current Ratio7.80
Quick Ratio6.78
Debt to Market Cap0.25
Net Debt to EBITDA2.12
Interest Coverage Ratio30.48
Taxes
In the past 12 months, Halozyme has paid 113.04M in taxes.
Income Tax113.04M
Effective Tax Rate0.20
Enterprise Valuation
Halozyme EV to EBITDA ratio is 11.35, with an EV/FCF ratio of 15.91.
EV to Sales7.34
EV to EBITDA11.35
EV to Free Cash Flow15.91
EV to Operating Cash Flow15.56
Balance Sheet
Halozyme has $596.07M in cash and marketable securities with $1.51B in debt, giving a net cash position of $909.72M billion.
Cash & Marketable Securities$596.07M
Total Debt$1.51B
Net Cash$909.72M
Net Cash Per Share$7.38
Tangible Book Value Per Share-$3.59
Margins
Gross margin is 80.80%, with operating margin of 54.32%, and net profit margin of 43.74%.
Gross Margin80.80%
Operating Margin54.32%
Pretax Margin54.87%
Net Profit Margin43.74%
EBITDA Margin64.66%
EBIT Margin56.65%
Analyst Forecast
The average price target for Halozyme is $68.44, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$68.44
Price Target Upside2.79% Upside
Analyst ConsensusModerate Buy
Analyst Count9
Revenue Growth Forecast25.65%
EPS Growth Forecast57.10%